• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Sunshine Biopharma Inc.

    4/11/25 5:02:07 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SBFM alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Sunshine Biopharma Inc.

    (Name of Issuer)


    Common Stock, $0.001 par value

    (Title of Class of Securities)


    867781700

    (CUSIP Number)


    04/02/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    867781700


    1Names of Reporting Persons

    BIGGER CAPITAL FUND L P
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    297,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    297,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    297,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.17 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    867781700


    1Names of Reporting Persons

    Bigger Capital Fund GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    297,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    297,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    297,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.17 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    867781700


    1Names of Reporting Persons

    Bigger Michael
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    297,101.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    297,101.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    297,101.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.17 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Sunshine Biopharma Inc.
    (b)Address of issuer's principal executive offices:

    333 Las Olas Way, CU4, Suite 433, Fort Lauderdale, FL 33301
    Item 2. 
    (a)Name of person filing:

    Bigger Capital Fund, LP ("Bigger Capital") Bigger Capital Fund GP, LLC ("Bigger GP") Michael Bigger Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    Bigger Capital Fund, LP 11700 W Charleston Blvd. 170-659 Las Vegas, NV 89135 Bigger Capital Fund GP, LLC 11700 W Charleston Blvd. 170-659 Las Vegas, NV 89135 Michael Bigger 11700 W Charleston Blvd. 170-659 Las Vegas, NV 89135
    (c)Citizenship:

    Bigger Capital Fund, LP Delaware Bigger Capital Fund GP, LLC Delaware Michael Bigger USA
    (d)Title of class of securities:

    Common Stock, $0.001 par value
    (e)CUSIP No.:

    867781700
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    As of April 2, 2025, Bigger Capital beneficially owned 297,101 shares of Common Stock. Bigger GP, as the general partner of Bigger Capital, may be deemed to beneficially own the Issuer's securities described herein. Mr. Bigger, as the managing member Bigger GP, the general partner of Bigger Capital, may be deemed to beneficially own the Issuer's securities described herein beneficially owned by Bigger Capital. The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person or any other person. Each of Bigger GP and Mr. Bigger disclaims beneficial ownership of the shares of Common Stock beneficially owned by Bigger Capital. The filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
    (b)Percent of class:

    The following percentages are based on 3,635,945 shares of Common Stock outstanding immediately after the offering based upon the Issuer's Prospectus Supplement filed under Rule 424(b)(5) with the Securities and Exchange Commission on April 3, 2025. As of the close of business on April 2, 2025, each of Bigger Capital and Bigger GP may be deemed to beneficially own approximately 8.17% of the outstanding shares of Common Stock. As of the close of business on April 2, 2025, Mr. Bigger may be deemed to beneficially own approximately 8.17% of the outstanding shares of Common Stock.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Bigger GP and Mr. Bigger may be deemed to share voting and dispositive power over the shares of Common Stock beneficially owned by Bigger Capital.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit 99.1.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BIGGER CAPITAL FUND L P
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member of Bigger Capital Fund GP, LLC, its general partner
    Date:04/11/2025
     
    Bigger Capital Fund GP, LLC
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger, Managing Member
    Date:04/11/2025
     
    Bigger Michael
     
    Signature:/s/ Michael Bigger
    Name/Title:Michael Bigger
    Date:04/11/2025
    Get the next $SBFM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBFM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SBFM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT

      FORT LAUDERDALE, FL / ACCESS Newswire / January 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs.The newly launched drugs are Olanzapine and Olanzapine ODT. Olanzapine is a generic version of Zyprexa®. Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders. Olanzapine is also indicated for the acute treatment of manic or mixed episodes of bipolar I disorder.

      1/21/25 8:00:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

      FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutic

      1/15/25 8:00:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus

      FORT LAUDERDALE, FL / ACCESSWIRE / December 9, 2024 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has developed an orally active protease inhibitor with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2).There are still unmet medical needs for agents to combat SARS-CoV-2 infections. SARS-CoV-2 is the etiologic agent of COVID-19 and one of three types of Coronavirus that cause Severe Acute Respiratory Syndrome (SARS). SARS-CoV-2 undergoes mutation at a rapid rate, which leads to the con

      12/9/24 7:30:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SBFM
    Leadership Updates

    Live Leadership Updates

    See more
    • Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

      FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutic

      1/15/25 8:00:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SBFM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

      SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

      11/14/24 4:28:14 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sunshine Biopharma Inc.

      SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)

      2/23/24 4:03:01 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sunshine Biopharma Inc.

      SC 13G - Sunshine Biopharma, Inc (0001402328) (Subject)

      2/21/24 4:28:39 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SBFM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

      4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

      3/5/24 4:05:35 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slilaty Steve N. bought $2,000 worth of Series B Preferred Stock (20,000 units at $0.10), increasing direct ownership by 200% to 30,000 units (SEC Form 4)

      4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

      2/12/24 4:05:15 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SBFM
    SEC Filings

    See more
    • Sunshine Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

      5/19/25 5:06:14 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Sunshine Biopharma Inc.

      10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)

      5/15/25 4:06:03 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Sunshine Biopharma Inc.

      SCHEDULE 13G - Sunshine Biopharma Inc. (0001402328) (Subject)

      4/11/25 5:02:07 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SBFM
    Financials

    Live finance-specific insights

    See more
    • Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue

      MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: "SBFM"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has completed the acquisition of all the outstanding shares of Nora Pharma Inc., effective immediately. As such, Nora Pharma Inc. is now a wholly owned subsidiary of Sunshine Biopharma Inc. Nora Pharma is one of North America's fastest growing generic pharmaceuticals companies. The addition of Nora Pharma allows Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars. The purchase price of $30,000,000 Canadian (approxi

      10/20/22 8:00:00 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SBFM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Roy Michel claimed ownership of 1 shares (SEC Form 3)

      3 - Sunshine Biopharma Inc. (0001402328) (Issuer)

      1/21/25 8:20:21 AM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

      4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

      3/5/24 4:05:35 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Slilaty Steve N. bought $2,000 worth of Series B Preferred Stock (20,000 units at $0.10), increasing direct ownership by 200% to 30,000 units (SEC Form 4)

      4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

      2/12/24 4:05:15 PM ET
      $SBFM
      Biotechnology: Pharmaceutical Preparations
      Health Care